NAD+ precursors in human aging: what the clinical evidence shows
One review summarizes clinical trials of NAD+ precursors in people and the questions that remain open. A second review covers the role of NAD+ in bacterial immunity.
Source: NAD+ precursors in human aging: review of clinical evidence (doi.org). Summary written with AI from the source and reviewed by rules; read the original.
What the research shows
A review published in October 2025 gathers clinical trials that tested supplementation with NAD+ precursors in humans. NAD+ is a molecule found in all cells and involved in many metabolic processes, and its precursors are substances the body can use to make it. According to the source, the review describes what these trials have established and which knowledge gaps persist. A second review, mentioned in the same source, covers the roles of NAD+ in bacterial immunity.
Context matters for a careful reading. Clinical trials are studies in which people receive an intervention and are compared with a control group, which allows effects to be assessed more reliably than observational studies allow. Even so, research on NAD+ and human aging still has open questions about which effects are consistent, in which people they appear, and for how long. Reviews like this organize what has been tested but do not replace the original studies. The source itself states that it does not recommend the use of these precursors.
What it means
The review indicates that a body of human trials with NAD+ precursors already exists, but it also points to gaps that remain unanswered. This means the topic is actively studied, without definitive conclusions about benefits in aging. Research still needs to show which effects are reliable and for which groups.
How to read it with care
This text summarizes a scientific review and does not replace a medical consultation. Anyone considering changes to diet, supplements, or any treatment should talk with a doctor or another qualified health professional before deciding.